Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article

Wang G, Qi K, Li X, Zuo S, Zhang R, Zhao Y, Sun S, Zhang J, Liu X (2024) · Cardiovascular Therapeutics · n=0

RCT evidence detailTrial reference

GRADE ModerateRCTBivalirudin: drug studies

Study Profile

Design: narrative systematic review of randomized controlled trials comparing heparin and bivalirudin anticoagulation in patients undergoing PCI for STEMI, NSTEMI, and unstable angina (Tangshan Gongren Hospital, China; Wuhan University; Harvard T.H. Chan)
Sample size (n): —
Intervention: Bivalirudin (synthetic hirudin-derived direct thrombin inhibitor) anticoagulation during PCI
Comparator: Unfractionated heparin (standard reference anticoagulant)
Primary endpoint: Composite of efficacy (ischemic events) and safety (bleeding events) outcomes from major RCTs
Primary result: Bivalirudin generally associated with lower bleeding rates than heparin in PCI for ACS; ischemic outcome equivalence varies by trial and ACS subtype; review reinforces clinical equipoise in some patient subgroups; demonstrates how synthetic hirudin-derivative pharmacology is studied via rigorous Phase-III pathways
Follow-up duration: Variable across cited RCTs (typically 30 days to 1 year)
PMID: 39749045

Key Findings

Bivalirudin generally associated with lower bleeding than heparin in PCI for ACS
Trial-by-trial heterogeneity in ischemic-event outcomes
Bivalirudin is a synthetic hirudin derivative (Angiomax) with established FDA approval
Demonstrates the drug-regulatory pathway distinct from K040187 device pathway
Useful pedagogical reference for explaining FDA drug vs FDA device distinctions

Limitations

Narrative synthesis without quantitative meta-analysis
Cited RCTs span multiple decades and PCI eras
Generalization across STEMI / NSTEMI / unstable angina subgroups limited
No new primary data
Not directly applicable to whole-leech hirudotherapy

Clinical Implications

Wang 2024 provides contemporary clinical-pharmacology context for bivalirudin — the synthetic hirudin derivative — within interventional cardiology. For ASH, the review serves as a regulatory and educational reference for distinguishing FDA-approved drug indications (synthetic hirudin derivatives) from the FDA K040187 device indication (whole-leech therapy). No direct US hirudotherapy clinical-practice implications.

Related Trials

Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial

Fuchs J, Cannon CP (1995)

Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial

Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW (2009)

Experience with pharmacologic leeching with bivalirudin for adjunct treatment of venous congestion of head and neck reconstructive flaps

Harun A, Kruer RM, Lee A, Boahene K, Byrne PJ, Richmon JD (2018)

Impact of Bivalirudin on Ischemia/Reperfusion Injury in Patients with Reperfused STEMI Assessed by Cardiac Magnetic Resonance

Zhang Y, Zou Z, Xu B, Chen B, Ge H, Ding S, Pu J (2024)

← Back to RCT Library